IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Bristol-Myers Squibb to Acquire Amylin Pharmaceuticals for $5.3 Billion

6:03 AM MDT | July 2, 2012 | Deepti Ramesh

Bristol-Myers Squibb (BMS; New York) and biopharmaceutical company Amylin Pharmaceuticals (San Diego, CA) say that BMS will acquire Amylin for $31/share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of about $5.3 billion. Amylin is focused on the discovery, development and commercialization of medicines for patients with diabetes and other metabolic diseases. The total value of the transaction, including Amylin’s net debt and a contractual payment obligation to Eli Lilly, together totaling about $1.7...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa